Bayer Healthcare LLC

Grifols Therapeutics Inc.

Talecris Biotherapeutics, Inc.

Jonathan S Strauss

Clark Qun Pan

Thomas Barnett

John E Murphy

Deqian Wang

Baisong Mei

Liang Tang

Hendri Tjandra

Jianmin Chen

James Rebbeor

Jeffrey A Yuziuk

Valery Novokhatny

Christopher J Stenland

Scott A Cook

Marina N Korneyeva

Jarrett C Terry

Rita T Bradley

Christopher A Dadd

Jonathan D Kent

Jiang Tang

Deqian Wamg

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.

Factor VIII conjugates

Disclosed is both a method for preparing a plasminogen and a method for preparing a reversibly inactive acidified plasmin by activating the plasminogen. The prepared plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The prepared plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.

Composition and method for preparing plasminogen

This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.

Site-directed modification of FVIII

Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.

Process for the production of a reversibly inactive acidified plasmin composition

Growing community of inventors

Walnut Creek, CA, United States of America

Jonathan S Strauss